Canadian journal of ophthalmology. Journal canadien d'ophtalmologie最新文献

{"title":"Switching from intravenous to subcutaneous tocilizumab for uveitis during the COVID-19 pandemic: a case series","authors":"Nitesh Mohan , Sunil K. Srivastava , Kimberly Baynes , Careen Y. Lowder , Sumit Sharma","doi":"10.1016/j.jcjo.2024.06.016","DOIUrl":"10.1016/j.jcjo.2024.06.016","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e181-e183"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated case of noninfectious and nontraumatic panophthalmitis","authors":"Farnaz Javadian , Niveditha Pattathil , James Farmer , Robert J. Campbell","doi":"10.1016/j.jcjo.2024.07.011","DOIUrl":"10.1016/j.jcjo.2024.07.011","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e176-e179"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"F. Y. EYE","authors":"","doi":"10.1016/j.jcjo.2024.12.010","DOIUrl":"10.1016/j.jcjo.2024.12.010","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Page 58"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitreoretinal metastasis from lung adenocarcinoma","authors":"Thomas M. Catapano, Deepthi E. Kurian, Tatyana Milman, Jason Hsu, Carol L. Shields","doi":"10.1016/j.jcjo.2024.07.020","DOIUrl":"10.1016/j.jcjo.2024.07.020","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e167-e170"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illuminated depressor enhanced fundus photography","authors":"Suma K. Thareja, Yasaman Ataei, Aparna Ramasubramanian","doi":"10.1016/j.jcjo.2024.09.001","DOIUrl":"10.1016/j.jcjo.2024.09.001","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Page e160"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration","authors":"Keean Nanji , Kevin Kennedy , Matthew Fung , Jim Xie , Amin Hatamnejad , Sunir J. Garg , Charles C. Wykoff , Varun Chaudhary","doi":"10.1016/j.jcjo.2024.05.027","DOIUrl":"10.1016/j.jcjo.2024.05.027","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the effect of the COVID-19 pandemic on injection intervals among patients treated for neovascular age-related macular degeneration.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Participants</h3><div>Patients treated at a single practice using a treat-and-extend regimen with intravitreal aflibercept between December 2018 and April 2021.</div></div><div><h3>Methods</h3><div>The primary outcome was the change in injection intervals. Secondary outcomes included differences in best-recorded visual acuity (BRVA) and central subfield thickness (CST). Associations were evaluated with linear mixed-effects modelling.</div></div><div><h3>Results</h3><div>This study included 1839 injections from 185 eyes (141 patients). The median (interquartile range) injection intervals in the pre-COVID-19 and COVID-19 periods were 60 (42–70) and 70 (49–90) days, respectively. The pandemic was associated with a mean injection interval lengthening of 7.2 days (<em>P</em> < 0.001), a decrease in BRVA of 3.1 Early Treatment Diabetic Retinopathy Study letters (<em>P</em> < 0.001), and a reduction in CST of 14.7 μm (<em>P</em> = 0.003). The presence of exudative intraretinal fluid was associated with a reduction in treatment intervals of 11.1 days (<em>P</em> < 0.001), a reduction in BRVA of 1.9 Early Treatment Diabetic Retinopathy Study letters (<em>P</em> < 0.001), and an increase in CST of 52.4 μm (<em>P</em> < 0.001). The presence of subretinal fluid was associated with a reduction in treatment intervals of 8.5 days (<em>P</em> < 0.001) and an increase in CST of 21.6 μm (<em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>This real-world study estimated that the severe acute respiratory syndrome coronavirus 2 pandemic resulted in an injection extension of 7.2 days with associated decreases in BRVA and CST that are unlikely clinically significant on a population basis. This builds on evidence suggesting that long-term vascular endothelial growth factor suppression can facilitate meaningful interval extensions while maintaining visual acuity.</div></div><div><h3>Objectif</h3><div>Mesurer l'effet de la pandémie de COVID-19 sur les intervalles entre les injections chez des patients traités en raison d'une dégénérescence maculaire liée à l’âge néovasculaire (DMLAn).</div></div><div><h3>Nature</h3><div>Étude de cohorte rétrospective.</div></div><div><h3>Participants</h3><div>Patients traités dans un centre unique selon un schéma thérapeutique « traitement-et-extension » qui ont reçu l'aflibercept par voie intravitréenne entre décembre 2018 et avril 2021.</div></div><div><h3>Méthodes</h3><div>Le paramètre principal était la modification des intervalles entre les injections. Les paramètres secondaires comprenaient les différences quant à la meilleure acuité visuelle enregistrée (MAVE) et à l’épaisseur du sous-champ central (ESC). Un modèle linéaire à effets mixtes a servi à é","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e92-e99"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in aqueous and vitreous inflammatory cytokine levels in nonproliferative diabetic retinopathy: systematic review and meta-analysis","authors":"Ryan H. Mason ,&nbsp;Samuel A. Minaker ,&nbsp;Gabriela Lahaie Luna ,&nbsp;Priya Bapat ,&nbsp;Armin Farahvash ,&nbsp;Anubhav Garg ,&nbsp;Nishaant Bhambra ,&nbsp;Rajeev H. Muni","doi":"10.1016/j.jcjo.2024.05.031","DOIUrl":"10.1016/j.jcjo.2024.05.031","url":null,"abstract":"<div><h3>Objectif</h3><div>La rétinopathie diabétique (RD) est une complication du diabète qui risque d'entraîner une morbidité significative. Si les altérations des cytokines inflammatoires intraoculaires sont au cœur de la pathogenèse de la RD, les études n'ont pas été en mesure de déterminer exactement quelles cytokines sont en cause. Nous avons donc réalisé un résumé quantitatif des cytokines pro-angiogéniques et proinflammatoires dans la RD non proliférante (RDNP), étant donné son incidence chez les patients atteints de diabète.</div></div><div><h3>Méthodes</h3><div>Une recherche systématique de la littérature médicale portant sur l'ensemble des bases de données jusqu'au 21 février 2022 inclusivement a permis de recenser 59 études mesurant les taux de cytokines dans le vitré et dans l'humeur aqueuse en présence de RDNP, qui regroupaient 1378 yeux atteints de RDNP et 1288 yeux de sujets témoins non diabétiques. La différence moyenne standardisée (DMS) a servi à comparer l'ampleur de l'effet des concentrations de cytokines chez les patients présentant une RDNP et les sujets témoins.</div></div><div><h3>Résultats</h3><div>Les concentrations (DMS, intervalle de confiance à 95 % et valeur de <em>p</em>) de l'interleukine-6 (IL-6) (2,58; 1,17–3,99; <em>p</em> = 0,0003), de l'IL-8 (1,56; 0,39–2,74; <em>p </em>= 0,009), de l'IL-17 (13,55; 7,50–19,59; <em>p</em> &lt; 0,001), du facteur de transformation de type bêta (TGF-β) (2,44; 1,02–3,85; <em>p</em> = 0,0007) et du facteur de croissance endothélial vasculaire (VEGF) (1,35; 0,76–1,93; <em>p</em> &lt; 0,00001) dans l'humeur aqueuse et du VEGF dans le vitré (1,49; 0,60–2,37; <em>p</em> = 0,001) étaient significativement plus élevées en présence de RDNP, comparativement à ce qui a été mesuré chez les sujets témoins sains.</div></div><div><h3>Conclusions</h3><div>Ces cytokines peuvent servir de marqueurs des altérations biochimiques qui se produisent dans la RDNP et peuvent orienter la prise en charge, tandis que nous amorçons une ère de schémas thérapeutiques plus ciblés.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e100-e116"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ChatGPT and retinal disease: a cross-sectional study on AI comprehension of clinical guidelines","authors":"Michael Balas ,&nbsp;Efrem D. Mandelcorn ,&nbsp;Peng Yan ,&nbsp;Edsel B. Ing ,&nbsp;Sean A. Crawford ,&nbsp;Parnian Arjmand","doi":"10.1016/j.jcjo.2024.06.001","DOIUrl":"10.1016/j.jcjo.2024.06.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the performance of an artificial intelligence (AI) large language model, ChatGPT (version 4.0), for common retinal diseases, in accordance with the American Academy of Ophthalmology (AAO) Preferred Practice Pattern (PPP) guidelines.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;A cross-sectional survey study design was employed to compare the responses made by ChatGPT to established clinical guidelines.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Responses by the AI were reviewed by a panel of three vitreoretinal specialists for evaluation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;To investigate ChatGPT's comprehension of clinical guidelines, we designed 130 questions covering a broad spectrum of topics within 12 AAO PPP domains of retinal disease These questions were crafted to encompass diagnostic criteria, treatment guidelines, and management strategies, including both medical and surgical aspects of retinal care. A panel of 3 retinal specialists independently evaluated responses on a Likert scale from 1 to 5 based on their relevance, accuracy, and adherence to AAO PPP guidelines. Response readability was evaluated using Flesch Readability Ease and Flesch-Kincaid grade level scores.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;ChatGPT achieved an overall average score of 4.9/5.0, suggesting high alignment with the AAO PPP guidelines. Scores varied across domains, with the lowest in the surgical management of disease. The responses had a low reading ease score and required a college-to-graduate level of comprehension. Identified errors were related to diagnostic criteria, treatment options, and methodological procedures.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;ChatGPT 4.0 demonstrated significant potential in generating guideline-concordant responses, particularly for common medical retinal diseases. However, its performance slightly decreased in surgical retina, highlighting the ongoing need for clinician input, further model refinement, and improved comprehensibility.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Évaluer les capacités d'un grand modèle de langage en intelligence artificielle (IA), soit ChatGPT (version 4.0), en ce qui a trait aux rétinopathies courantes, conformément aux lignes directrices en matière de pratiques courantes privilégiées (PPP, pour &lt;em&gt;Preferred Practice Pattern®&lt;/em&gt;) de l'American Academy of Ophthalmology (AAO).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Nature&lt;/h3&gt;&lt;div&gt;Il s'agit d'une enquête transversale visant à comparer les réponses du logiciel ChatGPT en fonction de lignes directrices cliniques établies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Les réponses du logiciel d'IA ont été évaluées par un panel de 3 spécialistes de l'ophtalmologie vitréorétinienne.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Afin d'examiner le degré de compréhension du logiciel ChatGPT en matière de lignes directrices cliniques, nous avons mis au point 130 questions portant sur un vaste ensemble de sujets qui s'inscrivaient dans les 12 domaines de ","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e117-e123"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual impairment, employment status, and reduction in income: the Canadian Longitudinal Study on Aging","authors":"Emma Iverson ,&nbsp;Mahadeo Sukhai ,&nbsp;Matthew P. Quinn ,&nbsp;Marie-Josée Aubin ,&nbsp;Ellen E. Freeman","doi":"10.1016/j.jcjo.2024.04.006","DOIUrl":"10.1016/j.jcjo.2024.04.006","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To examine the employment status of those with and without visual impairment and eye disease and to examine the association between visual impairment and eye disease and a reduction in income over a 3-year period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Population-based prospective cohort study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;A total of 12,174 nonretired participants aged 45–64 years old in the Canadian Longitudinal Study on Aging.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Visual impairment was defined if binocular presenting or pinhole-corrected monocular visual acuity in the better eye was worse than 20/40 at baseline. Self-reported diagnoses of age-related macular degeneration (AMD) and glaucoma were collected. Employment status (employed, not employed due to sickness or disability, or unemployed) was based on questions on labour force participation. Income reduction was defined as household income &lt;$50,000 per year at follow-up when household income was ≥$50,000 at baseline. Multinomial and logistic regressions were used to adjust for demographic and health variables.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Visual impairment using binocular presenting visual acuity (odds ratio [OR] = 2.09; 95% CI, 1.21–3.62) and pinhole-corrected visual acuity (OR = 2.99; 95% CI, 1.54–5.83) were associated with a higher odds of not being employed due to sickness or disability after adjustment. AMD (OR = 1.82; 95% CI, 1.11–3.01) and glaucoma (OR = 2.05; 95% CI, 1.28–3.28) at baseline were both associated with reductions in income over a 3-year period after adjustment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Individuals with visual impairment experienced lower employment, and those with AMD or glaucoma were more likely to have their incomes decline over 3 years. Policies to improve workplace participation by those with vision loss are needed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Examiner la situation de l'emploi en fonction de la déficience visuelle et des pathologies oculaires et analyser le lien entre la présence d'une déficience visuelle et d'une pathologie oculaire, d'une part, et une baisse des revenus sur une période de 3 ans, d'autre part.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Nature&lt;/h3&gt;&lt;div&gt;Étude de cohorte populationnelle prospective.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Un total de 12 174 participants à l’Étude longitudinale canadienne sur le vieillissement âgés de 45 à 64 ans qui n’étaient pas à la retraite.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;La déficience visuelle se définissait comme suit : acuité visuelle binoculaire au moment de l'examen ou acuité visuelle monoculaire corrigée au trou sténopéique du meilleur œil inférieure à 20/40 au départ. On a également consigné les diagnostics spontanément signalés de dégénérescence maculaire liée à l’âge (DMLA) et de glaucome. La situation de l'emploi (avec emploi, sans emploi en raison d'une maladie ou d'un handicap ou sans emploi) a été déterminée à partir de questions sur la présence","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e16-e22"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141135540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of noninfectious uveitis treated with systemic immunomodulatory therapy: a retrospective case series","authors":"Tina Felfeli ,&nbsp;Michael Balas ,&nbsp;Felicia Tai ,&nbsp;Arshia Eshtiaghi ,&nbsp;Jess Rhee ,&nbsp;Alexander J. Kaplan ,&nbsp;Panos G. Christakis ,&nbsp;Efrem D. Mandelcorn ,&nbsp;Nupura K. Bakshi ,&nbsp;Laurence A. Rubin ,&nbsp;Larissa A. Derzko-Dzulynsky","doi":"10.1016/j.jcjo.2024.05.005","DOIUrl":"10.1016/j.jcjo.2024.05.005","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To study the clinical characteristics and long-term outcomes of patients with noninfectious uveitis (NIU) who are treated with systemic immunomodulatory therapy (IMT).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective case series.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;All consecutive cases of adults with NIU under the care of 5 uveitis subspecialty tertiary care clinics between 2010 to 2021 were included.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Patient outcomes were assessed at initial presentation and at the latest available follow-up.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 418 NIU patients receiving IMT therapy with a median age of 46.0 years and 59.3% female were identified. Each patient required an average of 1.4 agents until achieving an optimal response. Following initial treatment with prednisone, patients were most commonly initiated on methotrexate. The top 3 treatments with the highest proportion of optimal treatment response when taken alone or in combination with other agents were infliximab (79.3%), cyclosporine (75%), and adalimumab (70%). The strongest predictors for requiring a greater number of IMTs trialed were younger age, panuveitis, and a chronic or recurrent disease course. Multivariable linear regression analysis suggested that baseline visual acuity at diagnosis was the only significant predictor of final visual acuity (&lt;em&gt;p&lt;/em&gt; &lt; 0.001).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;NIU patients on IMT are often trialed on multiple therapeutic agents before achieving an optimal treatment response. Visual acuity at diagnosis is a predictor of final visual outcomes, whereas chronic or recurrent disease course, younger age, and panuveitis are predictors of requiring multiagent treatment regimens.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Étudier les caractéristiques cliniques et les résultats à long terme des patients présentant une uvéite non infectieuse (UNI) qui reçoivent un immunomodulateur (IM) par voie générale.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Nature&lt;/h3&gt;&lt;div&gt;Série de cas rétrospectifs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Ont été inclus tous les adultes consécutifs qui présentaient une UNI et qui étaient traités dans 5 cliniques de soins tertiaires spécialisées dans l'uvéite entre 2010 et 2021.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;Les résultats ont été évalués lors de l'examen initial et au moment du dernier suivi figurant au dossier.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Au total, 418 patients (âge médian : 46,0 ans; 59,3 % de sexe féminin) atteints d'UNI ont reçu un IM. Chaque patient a dû recevoir en moyenne 1,4 médicament différent avant d'obtenir une réponse optimale. Après l'administration initiale de prednisone, les patients ont le plus souvent reçu le méthotrexate. Les 3 médicaments qui ont donné la proportion la plus élevée de réponse optimale ont été administrés seuls ou en association avec d'autres médicaments; il s'agissait de l'infliximab (79,3 %), de la cyclosporine (75 %) et","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e133-e143"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141407841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}